Radionuclide Conjugates 225Ac-J591 And 177Lu-Psma-I&T For Mcrpc

Radionuclide conjugates 225Ac-J591 and 177Lu-PSMA-I&T for mCRPC

PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPC

PSMA PET findings in 225AC-J591-treated patients with mCRPC

A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC patients

PSMA-targeted alpha emitter 225Ac-J591 for mCRPC

Phase I/II dose-escalation study of 225Ac-J591 in progressive mCRPC

World Theranostics Presentation: TTV on F18-PSMA PET to monitor treatment response of 225Ac-PSMA-I&T

Hermes Medical Solutions

177Lu-PSMA I&T for patients with PSMA-positive mCRPC

ECLIPSE - A Randomized Phase 3 Trial for 177-Lu-PSMA-I&T in patients with mCRPC

Science Animated

Safety and Efficacy of 177Lu-PSMA-617

GU Oncology Now

Unanswered questions in PSMA-targeted radionuclide therapy

Just the Beginning: What's Next for Radiotheranostics in Prostate Cancer?

Grand Rounds in Urology

177Lu-PSMA-617 radionuclide therapy in mCRPC

Dr. Tagawa on Preliminary Data With 225Ac-J591 in mCRPC

Phase I Trial Of 225Ac-J591 In Metastatic Castration-Resistant Prostate Cancer

Phase I/II Trial of 177Lu−J591 and 177Lu−PSMA−617 in mCRCP

Prostate cancer PSMA imaging and radionuclide therapy

Real-world outcomes of 177Lu-PSMA-617 in mCRPC

Oliver Sartor, MD, regarding recent outcomes investigating 225Ac-PSMA-617 in patients with APC

The benefits of 177Lu-PSMA-617 plus olaparib for prostate cancer